ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Published Date: 17 Apr 2026

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

Read Full News

Latest News

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Todays Updates

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Todays Updates

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Latest News

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

News All Time

France Expands 2026 Vaccination Rules Amid Resurgence

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage

3.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

4.

When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.

5.

EMA Backs Breast Cancer SERD After FDA No Vote

1.

Exploring the Latest Treatments for Essential Thrombocythemia

2.

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control

3.

Treating Methemoglobinemia: What You Need to Know Now!

4.

Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications

5.

Understanding Histiocytosis: Symptoms, Causes, and Treatment Options

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I

2.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

4.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

5.

Updates on the First Line Management of ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Latest News

Snus Linked to Gingival Damage, Raising Safety Questions

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Teclistamab Alone Ups Previously Treated Myeloma Survival

Therapy Combo Improves Radiographic PFS in Prostate Cancer

Abemaciclib Slows Progression of Advanced Liposarcoma

Trial Supports Ivonescimab and Chemo for NSCLC Survival

Todays Updates

Chiauranib Slows Platinum-Resistant Ovarian Cancer

Todays Updates

Chiauranib Slows Platinum-Resistant Ovarian Cancer

Latest News

News All Time

France Expands 2026 Vaccination Rules Amid Resurgence

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Too Many Chest CTs for Incidental Lung Nodules?

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

All-Oral Treatment Combo for AML Earns FDA Nod

Low PSA May Not Fully Predict Survival in Prostate Cancer

Only 1 in 4 Eligible Adults Receive Lung Screening

FDA Warns of Secondary Blood Cancer Risk With Tazverik

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

When Healthcare Chatbots Fall Short of Human Connection

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

FDA Advisors Split on Regimens for Breast, Prostate Cancers

Combo Therapy Boosts Early CML Response but Not Long Term

Recommended News For You

Prior authorizations draining time, energy from many cancer patients